TTT

THIOGENESIS THERAPEUTICS CORP

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪25.68 M‬CAD
−0.11CAD
‪−5.06 M‬CAD
0.00CAD
‪34.43 M‬
Beta (1Y)
−0.13

About THIOGENESIS THERAPEUTICS CORP


Sector
CEO
Patrice P. Rioux
Headquarters
Toronto
Founded
2018
FIGI
BBG00PPXD1P0
Thiogenesis Therapeutics Corp. engages in developing novel drug formulations that act as precursors for rare diseases. The company was founded in 2018 and is headquartered in Toronto, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of TTI is 0.58 CAD — it has decreased by −1.67% in the past 24 hours. Watch THIOGENESIS THERAPEUTICS CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSXV exchange THIOGENESIS THERAPEUTICS CORP stocks are traded under the ticker TTI.
TTI stock has fallen by −1.67% compared to the previous week, the month change is a −11.94% fall, over the last year THIOGENESIS THERAPEUTICS CORP has showed a −24.68% decrease.
TTI reached its all-time high on Jan 22, 2024 with the price of 1.06 CAD, and its all-time low was 0.10 CAD and was reached on Sep 3, 2019. View more price dynamics on TTI chart.
See other stocks reaching their highest and lowest prices.
TTI stock is 7.27% volatile and has beta coefficient of −0.13. Track THIOGENESIS THERAPEUTICS CORP stock price on the chart and check out the list of the most volatile stocks — is THIOGENESIS THERAPEUTICS CORP there?
Today THIOGENESIS THERAPEUTICS CORP has the market capitalization of ‪25.68 M‬, it has increased by 0.84% over the last week.
Yes, you can track THIOGENESIS THERAPEUTICS CORP financials in yearly and quarterly reports right on TradingView.
THIOGENESIS THERAPEUTICS CORP is going to release the next earnings report on Nov 18, 2024. Keep track of upcoming events with our Earnings Calendar.
TTI net income for the last quarter is ‪−651.32 K‬ CAD, while the quarter before that showed ‪−710.57 K‬ CAD of net income which accounts for 8.34% change. Track more THIOGENESIS THERAPEUTICS CORP financial stats to get the full picture.
No, TTI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TTI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade THIOGENESIS THERAPEUTICS CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So THIOGENESIS THERAPEUTICS CORP technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating THIOGENESIS THERAPEUTICS CORP stock shows the strong sell signal. See more of THIOGENESIS THERAPEUTICS CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.